Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 15;15:209–222. doi: 10.2147/DDDT.S282660

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Fan et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of prophylactic subcutaneous vaccination with H₂O₂-inactivated RE88-pVLT33-OVA on tumor growth in mice. (A) Photographs of tumors excised from mice in the various experimental groups (n = 7 per group). (B) Tumor weight (n = 7 per group). (C and D) Activation of T cells isolated from the spleen 1 week after the last immunization in mice immunized subcutaneously with various doses of vaccine. The cells were immunostained for CD4, CD8, and IFN-γ. Data are presented as mean ± SEM (n ≥ 3), *P < 0.05, **P < 0.01. NS: Normal saline (negative control); RE88: unmodified strain; RE88OVA: H₂O₂-inactivated RE88-pVLT33-OVA (3 doses); OVA-10 µg (positive control).